Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for ARS Pharmaceuticals (SPRY) over the last 5 years, with Dec 2024 value amounting to $72.4 million.

  • ARS Pharmaceuticals' Cash from Financing Activities rose 14612.50% to $100.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $174.4 million, marking a year-over-year increase of 5203.62%. This contributed to the annual value of $72.4 million for FY2024, which is 949.41% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $72.4 million for FY2024, which was up 949.41% from $6.9 million recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' Cash from Financing Activities ranged from a high of $408.5 million in FY2020 and a low of $6.9 million during FY2023.
  • For the 3-year period, ARS Pharmaceuticals' Cash from Financing Activities averaged around $90.0 million, with its median value being $72.4 million (2024).
  • Per our database at Business Quant, ARS Pharmaceuticals' Cash from Financing Activities tumbled by 96.38% in 2023 and then spiked by 949.41% in 2024.
  • Over the past 5 years, ARS Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $408.5 million in 2020, then crashed by 86.99% to $53.2 million in 2021, then surged by 258.80% to $190.7 million in 2022, then plummeted by 96.38% to $6.9 million in 2023, then surged by 949.41% to $72.4 million in 2024.